Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, randomized, placebo-controlled study of the efficacy, safety/tolerability, and pharmacokinetic profile of UCB0942 in adult patients with highly drug-resistant focal epilepsy

Next Previous
Trial Profile

A double-blind, randomized, placebo-controlled study of the efficacy, safety/tolerability, and pharmacokinetic profile of UCB0942 in adult patients with highly drug-resistant focal epilepsy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Padsevonil (Primary)
  • Indications Partial epilepsies
  • Focus Proof of concept; Therapeutic Use
  • Sponsors UCB

Most Recent Events

  • 11 May 2018 According to UCB Media release, data from this trial will be presented at EILAT Conference.
  • 05 Dec 2017 Primary endpoint has not been met. (75 % responder rate (75 % RR, proportion of subjects who achieve 75 % reduction in focal seizure frequency))
  • 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top